Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954668 | 0.85 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2878161 | 0.85 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL599783 | 0.84 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2873485 | 0.84 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL16249232 | 0.83 | NR1H2 (0.41) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL29955354 | 0.83 | TRPV3 (0.50) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2790380 | 0.83 | TRPV3 (0.50) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL759757 | 0.83 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL18445225 | 0.80 | NR1H2 (0.41) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL19013034 | 0.80 | CHRM2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470540-B1 | NOVEL FORMS OF A MULTICYCLIC COMPOUND | CEPHALON INC (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2791120-B1 | 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-02-24 | — | — | EP | disclosed |
| US-9115121-B2 | 1,3,5-triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof | SANOFI (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20140343061-A1 | 1,3,5 -Triazine-2-Amine Derivatives, Preparation Thereof And Diagnostic And Therapeutic Use Thereof | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| EP-2791120-A1 | 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-8633314-B2 | Forms of a multicyclic compound | CEPHALON, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633314-B2 | Forms of a multicyclic compound | CEPHALON, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| WO-2013087643-A1 | 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-06-20 | — | — | WO | disclosed |
| US-20120214998-A1 | Novel forms of a multicyclic compound | CEPHALON, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214998-A1 | Novel forms of a multicyclic compound | CEPHALON, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2011028580-A1 | NOVEL FORMS OF A MULTICYCLIC COMPOUND | CEPHALON, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (publ) (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | NR1H2 784/4885CHRM2 751/4885CHRM4 1649/4885 |
| US-20140343061-A1 | 1,3,5 -Triazine-2-Amine Derivatives, Preparation Thereof And Diagnostic And Therapeutic Use Thereof | ALK, HRH3, HRH4 | NR1H2 2088/4885CHRM2 135/4885CHRM4 498/4885 |
| US-20120214998-A1 | Novel forms of a multicyclic compound | CYP11B2, CYP11B1, CYP11A1 | NR1H2 390/4885CHRM2 2370/4885CHRM4 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.